Male Hypogonadism Exercise Prescription: What the Evidence Actually Supports

What Training Did to Resting Testosterone

Eleven randomized controlled trials enrolled 421 insufficiently active, apparently healthy men aged 19 to 75, using aerobic, resistance or combined programs for a median of 12 weeks [1]. The pooled effect on resting total testosterone was 0.00 (95% CI -0.20 to 0.20), and the response did not differ significantly by training mode, age, body mass or type of testosterone measurement [1]. The authors concluded that exercise training does not seem to affect resting total or free testosterone in these men [1].

Weight Loss in Obesity-Associated Low Testosterone

A 2013 meta-analysis pooled 24 articles on weight loss and sex hormones; 22 evaluated a low-calorie diet or bariatric surgery and two compared the two, so exercise programs were not the intervention tested [2]. Both approaches were associated with higher total testosterone versus baseline (P<0.0001), with a larger rise after surgery (8.73, range 6.51 to 10.95) than after low-calorie diet (2.87, range 1.68 to 4.07) [2]. The rise was greater in men who lost more weight, and degree of weight loss was the best determinant of the testosterone increase (B=2.50±0.98, P=0.029) [2].

How Hypogonadism Is Diagnosed

The Endocrine Society recommends diagnosing hypogonadism only with symptoms and signs of testosterone deficiency plus unequivocally and consistently low serum testosterone, measured fasting in the morning and confirmed by repeating the test [3]. The AUA guideline treats a total testosterone below 300 ng/dL as supporting the diagnosis only when symptoms or signs are also present and two early-morning measurements on separate occasions are low [4]. Harmonized values in healthy non-obese men aged 19 to 39 ran from 264 to 916 ng/dL (2.5th to 97.5th percentile), median 531 [6].

If Testosterone Is Prescribed

FDA-approved testosterone products are for men with low testosterone and an associated medical condition; FDA states that none is approved for low testosterone without one [7]. The Testim label states that safety and efficacy in men with age-related hypogonadism have not been established, and FDA requested labeling updates in June 2026 that included removing that limitation [5][7].

First-year monitoring covers symptoms, adverse effects, adherence, serum testosterone, hematocrit and prostate cancer risk [3]. Hematocrit is checked before and during treatment, and because testosterone can raise blood pressure, blood pressure is monitored periodically [3]. In TRAVERSE, major cardiovascular events occurred in 7.0% of men on 1.62% testosterone gel versus 7.3% on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [8]. Testosterone suppresses spermatogenesis, and the Endocrine Society recommends against starting it in men planning fertility in the near term [3].